Only 1 of 25 cancer drug developers fairly included minority patients over five-year window, BMJ analysis finds
New clinical trial diversity plans, which FDA will soon explain further, were featured in the government spending package that President Joe Biden signed late last week and are coming at a time when they’re very much needed, according to a new analysis published in the BMJ today.
Of the 25 companies reviewed for the new diversity rankings, United Therapeutics was the only one with a perfect fair inclusion score of 100, but seven others — Puma Biotechnology, Sanofi, Takeda, Amgen, Bristol Myers Squibb, Eli Lilly, and Merck KGaA — received a score in the top quartile on clinical trial diversity performance, according to the analysis from Stanford, Yale and Bioethics International researchers, which was supported by a grant from the Susan G. Komen Foundation.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters